Monthly Archives: December 2019

sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population

Data from more than 2,000 patients enrolled in the FROG-ICU study demonstrate that high levels of bioactive adrenomedullin (bio-ADM®) predict the need for organ support, ionotropes, and vasopressors in the general patient population at admission to the intensive care unit (ICU). bio-ADM® screening of patients admitted for septic or non-septic reasons supports stratification of risk…
Read more

sphingotec’s biomarker penKid® predicts septic acute kidney injury at time of admission to emergency department

Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKid® (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED). High penKid® plasma levels identified all ED patients with hidden AKI and AKI at admission and reflected worsening of kidney function. penKid® point-of-care (POC) implementation…
Read more

sphingotec’s proprietary biomarker bio-ADM® detects residual congestion in patients with heart failure

Data from more than 1,200 patients of the PROTECT study demonstrate that high levels of the endothelial function biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion of heart failure patients. Endothelial dysfunction, indicated by high bio-ADM® levels, leads to fluid leakage from blood vessels and ultimately resulting in tissue congestion. With 25% of heart failure patients…
Read more